Navigating Uncharted Territory

TIMING:

9:00am - 12:30pm Workshop; 8:30am- 9:00am registration

DESCRIPTION:

The field of mental health is rapidly evolving, perhaps nowhere as fervently as in the niche of psychedelics. The recent boom in psychedelic science and subsequent introduction of transformational medicines as viable and evidence-based treatments for some of the most intractable psychiatric disorders warrants the attention of clinicians and laypeople alike. This continuing education (CE) course is intended to provide an overview of the current, and rapidly evolving, landscape of psychedelics within the broader field of mental health. Through participation in this course, clinicians of all experience levels will gain a high-level understanding of where current research and policy is regarding the clinical use of psychedelic substances for various psychiatric disorders, gaps in the literature, applications of research into clinical practice, as well as where the field may be headed in the future.

Learning Objectives:

After completing this workshop, participants will be able to:

• Explain what aspects of PTSD are targeted in MDMA-assisted psychotherapy.
• Compare ketamine and psilocybin-assisted treatment for Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD).
• Describe the difference between psychedelic and psycholytic dosing in ketamine treatment.
• Identify 1 variable shown to mediate outcomes in psychedelic research.

CE Credits: 3.5 CE Hours

PSYCHOLOGISTS: The Wright Institute is approved by the American Psychological Association to sponsor continuing education for psychologists. The Wright Institute maintains responsibility for this program and its content.

CALIFORNIA LMFTs, LCSW, LEPs, & LPCCs: State of California Board of Behavioral Sciences (BBS) no longer approves continuing education providers. All providers have been removed from the provider list. As a replacement the board now accepts courses completed from a provider that has been approved by a number of different agencies. The Wright Institute is approved by the APA. All courses on this site are accepted for continuing education credit by the California Board of Behavioral Sciences.

Bio:

Dr. Rebecca Rothberg is a Berkeley-based psychotherapist, with a background in the arts, trauma-informed yoga, and working with non-ordinary states of consciousness in both research and clinical settings. She has served on clinical trials involving psychedelics at the Columbia University Medical Center, and published research investigating the role of mystical experience in ketamine treatment for substance use disorders. Dr. Rebecca has co-founded the Graduate Student Association for Psychedelic Studies (GSAPS), and trained with the Multidisciplinary Association for Psychedelic Studies (MAPS), Polaris Insight Center in San Francisco, VA Palo Alto Healthcare System, and Stanford Addiction Medicine Dual Diagnosis Clinic. She currently provides ketamine-assisted psychotherapy (KAP) in her private practice.